Literature DB >> 12366839

Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37.

Artur Schmidtchen1, Inga-Maria Frick, Emma Andersson, Hans Tapper, Lars Björck.   

Abstract

Effectors of the innate immune system, the anti-bacterial peptides, have pivotal roles in preventing infection at epithelial surfaces. Here we show that proteinases of the significant human pathogens Pseudomonas aeruginosa, Enterococcus faecalis, Proteus mirabilis and Streptococcus pyogenes, degrade the antibacterial peptide LL-37. Analysis by mass spectrometry of fragments generated by P. aeruginosa elastase in vitro revealed that the initial cleavages occurred at Asn-Leu and Asp-Phe, followed by two breaks at Arg-Ile, thus inactivating the peptide. Proteinases of the other pathogens also degraded LL-37 as determined by SDS-PAGE. Ex vivo, P. aeruginosa elastase induced LL-37 degradation in human wound fluid, leading to enhanced bacterial survival. The degradation was blocked by the metalloproteinase inhibitors GM6001 and 1, 10-phenantroline (both of which inhibited P. aeruginosa elastase, P. mirabilis proteinase, and E. faecalis gelatinase), or the inhibitor E64 (which inhibited S. pyogenes cysteine proteinase). Additional experiments demonstrated that dermatan sulphate and disaccharides of the structure [DeltaUA(2S)-GalNAc(4,6S)], or sucroseoctasulphate, inhibited the degradation of LL-37. The results indicate that proteolytic degradation of LL-37 is a common virulence mechanism and that molecules which block this degradation could have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12366839     DOI: 10.1046/j.1365-2958.2002.03146.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  153 in total

Review 1.  Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.

Authors:  Mattias Collin; Arne Olsén
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

Review 2.  Endogenous production of antimicrobial peptides in innate immunity and human disease.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

3.  Chlamydial plasmid-encoded virulence factor Pgp3 neutralizes the antichlamydial activity of human cathelicidin LL-37.

Authors:  Shuping Hou; Xiaohua Dong; Zhangsheng Yang; Zhongyu Li; Quanzhong Liu; Guangming Zhong
Journal:  Infect Immun       Date:  2015-09-28       Impact factor: 3.441

Review 4.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

Review 5.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

6.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

7.  In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37.

Authors:  Thorgerdur Sigurdardottir; Pia Andersson; Mina Davoudi; Martin Malmsten; Artur Schmidtchen; Mikael Bodelsson
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 8.  Enterococcus infection biology: lessons from invertebrate host models.

Authors:  Grace J Yuen; Frederick M Ausubel
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

Review 9.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications.

Authors:  Ian M Carroll; Nitsan Maharshak
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

10.  Antimicrobial Polymer-Peptide Conjugates Based on Maximin H5 and PEG to Prevent Biofouling of E. coli and P. aeruginosa.

Authors:  Valerie Ortiz-Gómez; Victor D Rodríguez-Ramos; Rafael Maldonado-Hernández; José A González-Feliciano; Eduardo Nicolau
Journal:  ACS Appl Mater Interfaces       Date:  2020-09-30       Impact factor: 9.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.